Last reviewed · How we verify
recombinant interferon alfa-2b
Recombinant interferon alfa-2b works by stimulating the body's immune system to fight viral infections and cancer.
Recombinant interferon alfa-2b works by stimulating the body's immune system to fight viral infections and cancer. Used for Hairy cell leukemia, Chronic myelogenous leukemia, Multiple myeloma.
At a glance
| Generic name | recombinant interferon alfa-2b |
|---|---|
| Also known as | IFN 2b, Alfatronol, Bioferon, Bioferon (TM), Glucoferon |
| Sponsor | Case Comprehensive Cancer Center |
| Drug class | Interferon |
| Target | Interferon-alpha receptor |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
It does this by binding to the interferon-alpha receptor, which triggers a cascade of signaling events that ultimately lead to the production of antiviral and antiproliferative proteins. This helps to slow down or stop the growth of cancer cells and reduce the severity of viral infections.
Approved indications
- Hairy cell leukemia
- Chronic myelogenous leukemia
- Multiple myeloma
- Melanoma
- Kaposi's sarcoma
Common side effects
- Flu-like symptoms
- Fatigue
- Headache
- Myalgia
- Chills
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Rash
Key clinical trials
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (PHASE3)
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (PHASE3)
- Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia (PHASE2)
- Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma (PHASE2)
- Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer (PHASE1, PHASE2)
- A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer (PHASE3)
- A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV (NA)
- High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |